Replication of our findings in larger cohorts with matched postmortem data will be important, together with combination testing of α‐synuclein and 4RT SAAs across parkinsonian disorders to assess positive and negative predictive values of both assays in clinical and research settings. The gene discussed is PCSK1N; the disease is parkinsonian disorder.